Year: 2018
Type: article
Abstract: TO THE EDITOR:
The “unclassifiable” myelodysplastic/myeloproliferative neoplasms (MDS/MPN-U) remain the most poorly characterized among the various subtypes of MDS/MPN.[1][1] Retrospective studies have reported the median survival of patients with MDS/MPN-U to be 21 months from diagnosis[2][2]
Source: Blood
Authors: Prithviraj Bose, Aziz Nazha, Rami S. Komrokji, Keyur P. Patel, Sherry A. Pierce, Najla Al-Ali, Andrew Sochacki, Aaron Shaver, Wencai Ma, Xiaoping Su, Naval G. Daver, Courtney D. DiNardo, Guillermo Garcia-Manero, Sanam Loghavi, Carlos Bueso-Ramos, Hagop M. Kantarjian, Mikkael A. Sekeres, Michael R. Savona, Jaroslaw P. Maciejewski, Srdan Verstovsek
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: bronze
OpenAlex ID: W2892085072